Skip to main content

Leica Biosystems Finalist for 2022 Victorian Manufacturing Hall of Fame Award

The company’s latest Advanced Staining Solution, BOND-PRIME, is primarily manufactured in Melbourne, Australia

MELBOURNE – Leica Biosystems is pleased to announce that the company was a finalist for the 2022 Victorian Manufacturing Hall of Fame Award for Manufacturer of the Year (Large Business). The Leica Biosystems facility in Melbourne was established in 2000, where more than 300 associates manufacture solutions to be shipped to laboratories around the world.

The company’s latest product, the BOND-PRIME Advanced Staining Solution, is the only system that delivers all elements of Universal Access, enabling lab technicians to load any slides in any combination, with any reagent, at any time.

“BOND-PRIME is proudly manufactured here in Melbourne,” said Colin White, Senior Director of Advanced Staining and Imaging at Leica Biosystems. “While Leica Biosystems has a broad global footprint, a number of our Advanced Staining and Core Histology solutions are made here at our Mount Waverly facility, which has been in operation for more than 20 years.”

The Victorian Manufacturing Hall of Fame Awards celebrate the importance of local manufacturing and highlight the achievements made by manufacturers within the state. This year’s theme is ‘Made in Victoria.”

This is not the first recognition of its kind for Leica Biosystems. The company previously won the High Growth Sector – Medical Technology and Pharma Award at the 2018 Victorian Manufacturing Hall of Fame awards ceremony. In 2019, the company was a finalist for Manufacturer of the Year (Large Business).

About the BOND-PRIME Advanced Staining Solution

The BOND-PRIME staining platform delivers high productivity, featuring Universal Access, and can seamlessly adapt to your incoming workflow demands – whether it be batched, continuous, single slide or STAT cases, or a combination of all the above.

Coupled with the ability to produce high-quality, crisp, clean staining with an average IHC TAT of 90 minutes, the BOND-PRIME staining platform lets you transcend expectations for quality, timeliness, and diagnostic productivity.

Read more about BOND-PRIME here. This solution may not be available in your geography. For In Vitro Diagnostic Use.

About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Visit for more information.